Selection for this week
Some Pros about the stock
Some Cons about the stock
Criteria for choosing
The previous selections

Add: CNC (Centene) HealthCare Plans

What does the company do?

Centene Corporation (NYSE: CNC) is one of the largest managed healthcare providers in the United States, focusing on government-sponsored healthcare programs. The company operates through Medicaid, Medicare, Commercial, and Other Healthcare Services segments, offering health plans, pharmacy services, behavioral health, vision, and dental care. Centene serves millions of members through a nationwide network of physicians, hospitals, and healthcare providers. Founded in 1984, the company is headquartered in St. Louis, Missouri.

Why Some Investors Are Bullish

Blowout Q1 2026 earnings and strong cash generation

Centene reported Q1 2026 adjusted diluted EPS of approximately $3.37, significantly above analyst expectations, while revenue grew about 7% year-over-year. The company also generated roughly $4.4 billion in operating cash flow and reduced debt by approximately $1 billion, demonstrating that improved profitability is translating into real cash generation. The stock responded with a strong post-earnings rally.

Compelling valuation despite recent gains

Despite a sharp move higher following earnings, several analysts continue to see upside potential. Barclays raised its price target to $75 from $63, while Bank of America increased its target to $72, citing improving Medicaid margins and earnings potential. Shares still trade at valuation levels that many investors consider attractive relative to long-term earnings power.

Medical cost management is improving

The Medicaid Health Benefit Ratio (HBR) improved to approximately 93.1%, while Medicare HBR remained strong at approximately 84.9%. Management attributed the improvement to better utilization management, medical cost controls, and operational execution, suggesting the gains are supported by underlying business performance rather than one-time factors.

Dominant position in government-sponsored healthcare

Centene remains one of the largest Medicaid managed care organizations in the United States, serving millions of members across numerous states. Its scale provides advantages in contracting, provider networks, data analytics, and administrative efficiency that smaller competitors may struggle to match.

Raised full-year guidance signals confidence

Management raised full-year 2026 expectations following the strong quarter, signaling confidence that operational improvements and margin gains can continue. For a company of Centene’s size, increasing guidance after a single quarter is generally viewed as a positive indicator of business momentum.

What Bears Are Worried About

Medicaid policy and reimbursement risk

Changes to federal or state Medicaid funding remain the company’s largest long-term risk. Any reduction in reimbursement rates, funding levels, or program eligibility could negatively impact membership growth, revenue, and profitability.

ACA Marketplace uncertainty

Future changes to Affordable Care Act subsidies and Marketplace regulations could affect enrollment trends and profitability within Centene’s commercial business. While the segment continues to perform reasonably well, policy uncertainty remains an overhang.

Recent rally raises expectations

Following the strong earnings-driven advance, investor expectations have increased considerably. Future quarters will need to demonstrate continued margin improvement and earnings growth, leaving less room for execution missteps than before the earnings report.

Bottom Line

Centene’s investment case has improved significantly following its strong Q1 2026 results. Earnings, cash flow, debt reduction, and improving medical cost trends all support the bullish thesis, while the company’s scale in government-sponsored healthcare provides a durable competitive advantage. The primary risks remain policy-related uncertainty surrounding Medicaid and ACA programs, along with the challenge of sustaining recent operational momentum after a substantial post-earnings rally.

Top Quant Stock of the Week Criteria

Over the next few weeks, I will be detailing all the criteria I will use.

So far:

I am using a Quantitative research platform that provides a daily list of top-ranked stocks to buy or sell, based on a Comprehensive Quant Score. This Quant system uses computer algorithms to come up with its rankings. This score incorporates multiple factors, including valuation, growth, profitability, momentum, and EPS revisions.
I will be giving heavy weight to strong momentum and strong EPS revisions to make the weekly selection. Then, I will use my tested proprietary criteria to sort and then break any tie.

One stock will be selected each week. That would make 52 selections a year if I don’t miss any weeks because of internet problems.
The hold times for the stocks added will be 1 week to years. Although a 1 week hold would be rare, it could happen if the stocks Quant metrics took a big nose di.ve right after being selected. If an added stock maintains its good metrics, it will be kept in the portfolio until it doesn’t. No time limit. The Quant system will tell me when it is time to let it go. So the hold time is short, medium and long depending on the Quant system metrics.

All countries are included. ADR’s are ok but Pink Sheet stocks will not be allowed.
Certain Industries are excluded. My testing shows they do not perform well using Quantitative rankings. Two of the main ones are BioTechnology and Pharmacueticals.
The Sell Criteria: Once the stock no longer qualifies to be retained in the Portfolio, it will be removed. This could be because the companies metrics have deteriorated since selection, it is involved in a buyout or financial reporting problems.

Additional Criteria

Once a stock has been put on the Active list, it will not be added to. No doubling down.
When a stock is removed from the list, 100% is removed. No scaling out.
The stocks considered are larger small cap, mid cap, large cap and Mega cap. They will be fairly easy to trade with opening or closing market orders as one of the ways to enter and exit positions.
It should be expected that about 50 stocks will be Active in the Portfolio in any given week, once it gets to the two year mark.
All stocks are added as equal weight. No rebalancing is to occur.
To be considered for a Buy, the stock has to be in the top group of Quant rankings for just several weeks. This is to allow newly upgraded stocks to qualify quickly. Hopefully, this will catch a couple strong momentum stocks early in their move.

Previous Selections:

All content on this site is for informational purposes only and does not constitute financial advice. Consult relevant financial professionals in your country of residence to get personalized advice before you make any trading or investing decisions. This post was written with the assistance of artificial intelligence. The original ideas and final review are human-generated. Disclaimer